1 Min Read
Nov 27 (Reuters) - Jecure Therapeutics Inc:
* JECURE THERAPEUTICS INC SAYS GENENTECH WILL OBTAIN FULL RIGHTS TO CO’S ENTIRE PRECLINICAL PORTFOLIO OF NLRP3 INHIBITORS Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.